<li>alprazolam<p>alprazolam and hydrocodone both increase  pharmacodynamic synergism. Avoid or Use Alternate Drug. may result in profound sedation, respiratory depression, coma, and death; avoid use of opioid medications in patients taking benzodiazepines, other CNS depressants, or alcohol</p></li><li>artemether/lumefantrine<p>artemether/lumefantrine will increase the level or effect of hydrocodone by  affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug.</p></li><li>atazanavir<p>atazanavir will increase the level or effect of hydrocodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Coadministration with CYP3A4 inhibitors may increase hydrocodone plasma concentrations and can result in potentially fatal respiratory depression</p></li><li>boceprevir<p>boceprevir will increase the level or effect of hydrocodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Coadministration with CYP3A4 inhibitors may increase hydrocodone plasma concentrations and can result in potentially fatal respiratory depression</p></li><li>bosentan<p>bosentan will decrease the level or effect of hydrocodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Caution when discontinuing CYP3A4 inducers that are coadministered with hydrocodone; plasma concentrations of hydrocodone may increase and can result in potentially fatal respiratory depression</p></li><li>buprenorphine<p>buprenorphine, hydrocodone. Other (see comment). Avoid or Use Alternate Drug. 
Comment: Mixed opiate agonist/antagonists usually produce additive sedation with narcotics; however, in narcotic addicted pts., the antagonist activity may provoke withdrawal Sx.</p></li><li>buprenorphine buccal<p>buprenorphine buccal, hydrocodone. Other (see comment). Avoid or Use Alternate Drug. 
Comment: Mixed opiate agonist/antagonists usually produce additive sedation with narcotics; however, in narcotic addicted pts., the antagonist activity may provoke withdrawal Sx.</p></li><li>butorphanol<p>butorphanol, hydrocodone. Other (see comment). Avoid or Use Alternate Drug. 
Comment: Mixed opiate agonist/antagonists usually produce additive sedation with narcotics; however, in narcotic addicted pts., the antagonist activity may provoke withdrawal Sx.</p></li><li>carbamazepine<p>carbamazepine will decrease the level or effect of hydrocodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Caution when discontinuing CYP3A4 inducers that are coadministered with hydrocodone; plasma concentrations of hydrocodone may increase and can result in potentially fatal respiratory depression</p></li><li>chlordiazepoxide<p>chlordiazepoxide and hydrocodone both increase  pharmacodynamic synergism. Avoid or Use Alternate Drug. may result in profound sedation, respiratory depression, coma, and death; avoid use of opioid medications in patients taking benzodiazepines, other CNS depressants, or alcohol</p></li><li>cimetidine<p>cimetidine increases effects of hydrocodone by decreasing metabolism. Avoid or Use Alternate Drug.</p></li><li>clarithromycin<p>clarithromycin will increase the level or effect of hydrocodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Coadministration with CYP3A4 inhibitors may increase hydrocodone plasma concentrations and can result in potentially fatal respiratory depression</p></li><li>clobazam<p>clobazam and hydrocodone both increase  pharmacodynamic synergism. Avoid or Use Alternate Drug. may result in profound sedation, respiratory depression, coma, and death; avoid use of opioid medications in patients taking benzodiazepines, other CNS depressants, or alcohol</p></li><li>clonazepam<p>clonazepam and hydrocodone both increase  sedation. Avoid or Use Alternate Drug. may result in profound sedation, respiratory depression, coma, and death; avoid use of opioid medications in patients taking benzodiazepines, other CNS depressants, or alcohol</p></li><li>cobicistat<p>cobicistat will increase the level or effect of hydrocodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Coadministration with CYP3A4 inhibitors may increase hydrocodone plasma concentrations and can result in potentially fatal respiratory depression</p></li><li>conivaptan<p>conivaptan will increase the level or effect of hydrocodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Coadministration with CYP3A4 inhibitors may increase hydrocodone plasma concentrations and can result in potentially fatal respiratory depression</p></li><li>dabrafenib<p>dabrafenib will decrease the level or effect of hydrocodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Caution when discontinuing CYP3A4 inducers that are coadministered with hydrocodone; plasma concentrations of hydrocodone may increase and can result in potentially fatal respiratory depression</p></li><li>darunavir<p>darunavir will increase the level or effect of hydrocodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Coadministration with CYP3A4 inhibitors may increase hydrocodone plasma concentrations and can result in potentially fatal respiratory depression</p></li><li>delavirdine<p>delavirdine will increase the level or effect of hydrocodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Coadministration with CYP3A4 inhibitors may increase hydrocodone plasma concentrations and can result in potentially fatal respiratory depression</p></li><li>dexamethasone<p>dexamethasone will decrease the level or effect of hydrocodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Caution when discontinuing CYP3A4 inducers that are coadministered with hydrocodone; plasma concentrations of hydrocodone may increase and can result in potentially fatal respiratory depression</p></li><li>diazepam<p>diazepam and hydrocodone both increase  pharmacodynamic synergism. Avoid or Use Alternate Drug. may result in profound sedation, respiratory depression, coma, and death; avoid use of opioid medications in patients taking benzodiazepines, other CNS depressants, or alcohol</p></li><li>efavirenz<p>efavirenz will decrease the level or effect of hydrocodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Caution when discontinuing CYP3A4 inducers that are coadministered with hydrocodone; plasma concentrations of hydrocodone may increase and can result in potentially fatal respiratory depression</p></li><li>eluxadoline<p>hydrocodone, eluxadoline.
Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Avoid coadministration with other drugs that cause constipation. Increases risk for constipation related serious adverse reactions. .</p></li><li>enzalutamide<p>enzalutamide will decrease the level or effect of hydrocodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Caution when discontinuing CYP3A4 inducers that are coadministered with hydrocodone; plasma concentrations of hydrocodone may increase and can result in potentially fatal respiratory depression</p></li><li>eslicarbazepine acetate<p>eslicarbazepine acetate will decrease the level or effect of hydrocodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Caution when discontinuing CYP3A4 inducers that are coadministered with hydrocodone; plasma concentrations of hydrocodone may increase and can result in potentially fatal respiratory depression</p></li><li>etravirine<p>etravirine will decrease the level or effect of hydrocodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Caution when discontinuing CYP3A4 inducers that are coadministered with hydrocodone; plasma concentrations of hydrocodone may increase and can result in potentially fatal respiratory depression</p></li><li>fentanyl<p>fentanyl, hydrocodone.
Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration with other CNS depressants, such as skeletal muscle relaxants, may cause respiratory depression, hypotension,  profound sedation, coma, and/or death. Consider dose reduction of either or both agents to avoid serious adverse effects. Monitor for hypotension, respiratory depression, and profound sedation.</p></li><li>fentanyl intranasal<p>fentanyl intranasal, hydrocodone.
Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration with other CNS depressants, such as skeletal muscle relaxants, may cause respiratory depression, hypotension,  profound sedation, coma, and/or death. Consider dose reduction of either or both agents to avoid serious adverse effects. Monitor for hypotension, respiratory depression, and profound sedation.</p></li><li>fentanyl iontophoretic transdermal system<p>fentanyl iontophoretic transdermal system, hydrocodone.
Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration with other CNS depressants, such as skeletal muscle relaxants, may cause respiratory depression, hypotension,  profound sedation, coma, and/or death. Consider dose reduction of either or both agents to avoid serious adverse effects. Monitor for hypotension, respiratory depression, and profound sedation.</p></li><li>fentanyl transdermal<p>fentanyl transdermal, hydrocodone.
Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration with other CNS depressants, such as skeletal muscle relaxants, may cause respiratory depression, hypotension,  profound sedation, coma, and/or death. Consider dose reduction of either or both agents to avoid serious adverse effects. Monitor for hypotension, respiratory depression, and profound sedation.</p></li><li>fentanyl transmucosal<p>fentanyl transmucosal, hydrocodone.
Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration with other CNS depressants, such as skeletal muscle relaxants, may cause respiratory depression, hypotension,  profound sedation, coma, and/or death. Consider dose reduction of either or both agents to avoid serious adverse effects. Monitor for hypotension, respiratory depression, and profound sedation.</p></li><li>fosamprenavir<p>fosamprenavir will increase the level or effect of hydrocodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Coadministration with CYP3A4 inhibitors may increase hydrocodone plasma concentrations and can result in potentially fatal respiratory depression</p></li><li>fosphenytoin<p>fosphenytoin will decrease the level or effect of hydrocodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Caution when discontinuing CYP3A4 inducers that are coadministered with hydrocodone; plasma concentrations of hydrocodone may increase and can result in potentially fatal respiratory depression</p></li><li>gabapentin<p>gabapentin increases toxicity of hydrocodone by pharmacodynamic synergism. Avoid or Use Alternate Drug. Consider reducing initial hydrocodone dose by 20-30% when using concomitantly .</p></li><li>grapefruit<p>grapefruit will increase the level or effect of hydrocodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Coadministration with CYP3A4 inhibitors may increase hydrocodone plasma concentrations and can result in potentially fatal respiratory depression</p></li><li>idelalisib<p>idelalisib will increase the level or effect of hydrocodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Coadministration with CYP3A4 inhibitors may increase hydrocodone plasma concentrations and can result in potentially fatal respiratory depression</p></li><li>imatinib<p>imatinib will increase the level or effect of hydrocodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Coadministration with CYP3A4 inhibitors may increase hydrocodone plasma concentrations and can result in potentially fatal respiratory depression</p></li><li>isocarboxazid<p>isocarboxazid increases toxicity of hydrocodone by unknown mechanism. Avoid or Use Alternate Drug. Risk of hypotension, hyperpyrexia, somnolence, or death; separate by 14 d.</p></li><li>isoniazid<p>isoniazid will increase the level or effect of hydrocodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Coadministration with CYP3A4 inhibitors may increase hydrocodone plasma concentrations and can result in potentially fatal respiratory depression</p></li><li>itraconazole<p>itraconazole will increase the level or effect of hydrocodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Coadministration with CYP3A4 inhibitors may increase hydrocodone plasma concentrations and can result in potentially fatal respiratory depression</p></li><li>ketoconazole<p>ketoconazole will increase the level or effect of hydrocodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Coadministration with CYP3A4 inhibitors may increase hydrocodone plasma concentrations and can result in potentially fatal respiratory depression</p></li><li>linezolid<p>linezolid increases toxicity of hydrocodone by unknown mechanism. Avoid or Use Alternate Drug. Risk of hypotension, hyperpyrexia, somnolence, or death; separate by 14 d.</p></li><li>lopinavir<p>lopinavir will increase the level or effect of hydrocodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Coadministration with CYP3A4 inhibitors may increase hydrocodone plasma concentrations and can result in potentially fatal respiratory depression</p></li><li>lumefantrine<p>lumefantrine will increase the level or effect of hydrocodone by  affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug.</p></li><li>mitotane<p>mitotane will decrease the level or effect of hydrocodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Caution when discontinuing CYP3A4 inducers that are coadministered with hydrocodone; plasma concentrations of hydrocodone may increase and can result in potentially fatal respiratory depression</p></li><li>nafcillin<p>nafcillin will decrease the level or effect of hydrocodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Caution when discontinuing CYP3A4 inducers that are coadministered with hydrocodone; plasma concentrations of hydrocodone may increase and can result in potentially fatal respiratory depression</p></li><li>nalbuphine<p>nalbuphine, hydrocodone. Other (see comment). Avoid or Use Alternate Drug. 
Comment: Mixed opiate agonist/antagonists usually produce additive sedation with narcotics; however, in narcotic addicted pts., the antagonist activity may provoke withdrawal Sx.</p></li><li>naltrexone<p>naltrexone decreases levels of hydrocodone by pharmacodynamic antagonism. Avoid or Use Alternate Drug.</p></li><li>nefazodone<p>nefazodone will increase the level or effect of hydrocodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Coadministration with CYP3A4 inhibitors may increase hydrocodone plasma concentrations and can result in potentially fatal respiratory depression</p></li><li>nelfinavir<p>nelfinavir will increase the level or effect of hydrocodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Coadministration with CYP3A4 inhibitors may increase hydrocodone plasma concentrations and can result in potentially fatal respiratory depression</p></li><li>nevirapine<p>nevirapine will decrease the level or effect of hydrocodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Caution when discontinuing CYP3A4 inducers that are coadministered with hydrocodone; plasma concentrations of hydrocodone may increase and can result in potentially fatal respiratory depression</p></li><li>nicardipine<p>nicardipine will increase the level or effect of hydrocodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Coadministration with CYP3A4 inhibitors may increase hydrocodone plasma concentrations and can result in potentially fatal respiratory depression</p></li><li>oxazepam<p>oxazepam and hydrocodone both increase  sedation. Avoid or Use Alternate Drug. may result in profound sedation, respiratory depression, coma, and death; avoid use of opioid medications in patients taking benzodiazepines, other CNS depressants, or alcohol</p></li><li>oxcarbazepine<p>oxcarbazepine will decrease the level or effect of hydrocodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Caution when discontinuing CYP3A4 inducers that are coadministered with hydrocodone; plasma concentrations of hydrocodone may increase and can result in potentially fatal respiratory depression</p></li><li>paroxetine<p>paroxetine will increase the level or effect of hydrocodone by  affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug.</p></li><li>pentazocine<p>pentazocine, hydrocodone. Other (see comment). Avoid or Use Alternate Drug. 
Comment: Mixed opiate agonist/antagonists usually produce additive sedation with narcotics; however, in narcotic addicted pts., the antagonist activity may provoke withdrawal Sx.</p></li><li>pentobarbital<p>pentobarbital will decrease the level or effect of hydrocodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Caution when discontinuing CYP3A4 inducers that are coadministered with hydrocodone; plasma concentrations of hydrocodone may increase and can result in potentially fatal respiratory depression</p></li><li>phenelzine<p>phenelzine increases toxicity of hydrocodone by unknown mechanism. Avoid or Use Alternate Drug. Risk of hypotension, hyperpyrexia, somnolence, or death; separate by 14 d.</p></li><li>phenobarbital<p>phenobarbital will decrease the level or effect of hydrocodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Caution when discontinuing CYP3A4 inducers that are coadministered with hydrocodone; plasma concentrations of hydrocodone may increase and can result in potentially fatal respiratory depression</p></li><li>phenytoin<p>phenytoin will decrease the level or effect of hydrocodone by  affecting hepatic enzyme CYP2E1 metabolism. Avoid or Use Alternate Drug. Caution when discontinuing CYP3A4 inducers that are coadministered with hydrocodone; plasma concentrations of hydrocodone may increase and can result in potentially fatal respiratory depression</p></li><li>posaconazole<p>posaconazole will increase the level or effect of hydrocodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Coadministration with CYP3A4 inhibitors may increase hydrocodone plasma concentrations and can result in potentially fatal respiratory depression</p></li><li>primidone<p>primidone will decrease the level or effect of hydrocodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Caution when discontinuing CYP3A4 inducers that are coadministered with hydrocodone; plasma concentrations of hydrocodone may increase and can result in potentially fatal respiratory depression</p></li><li>procarbazine<p>procarbazine increases toxicity of hydrocodone by unknown mechanism. Avoid or Use Alternate Drug. MAOIs may potentiate CNS depression and hypotension. Do not use within 14 days of MAOI use. .</p></li><li>quazepam<p>quazepam and hydrocodone both increase  sedation. Avoid or Use Alternate Drug. may result in profound sedation, respiratory depression, coma, and death; avoid use of opioid medications in patients taking benzodiazepines, other CNS depressants, or alcohol</p></li><li>quinidine<p>quinidine will increase the level or effect of hydrocodone by  affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug.<span><br><br></span>quinidine will increase the level or effect of hydrocodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Coadministration with CYP3A4 inhibitors may increase hydrocodone plasma concentrations and can result in potentially fatal respiratory depression</p></li><li>rasagiline<p>rasagiline increases toxicity of hydrocodone by unknown mechanism. Avoid or Use Alternate Drug. May cause additive CNS depression, drowsiness, dizziness or hypotension, so use with MAOIs should be cautious; lower initial dosages of the analgesic are recommended followed by careful titration. Avoid combination within 14 days of MAOI use.</p></li><li>rifabutin<p>rifabutin will decrease the level or effect of hydrocodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Caution when discontinuing CYP3A4 inducers that are coadministered with hydrocodone; plasma concentrations of hydrocodone may increase and can result in potentially fatal respiratory depression</p></li><li>rifampin<p>rifampin will decrease the level or effect of hydrocodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Caution when discontinuing CYP3A4 inducers that are coadministered with hydrocodone; plasma concentrations of hydrocodone may increase and can result in potentially fatal respiratory depression</p></li><li>rifapentine<p>rifapentine will decrease the level or effect of hydrocodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Caution when discontinuing CYP3A4 inducers that are coadministered with hydrocodone; plasma concentrations of hydrocodone may increase and can result in potentially fatal respiratory depression</p></li><li>ritonavir<p>ritonavir will increase the level or effect of hydrocodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Coadministration with CYP3A4 inhibitors may increase hydrocodone plasma concentrations and can result in potentially fatal respiratory depression</p></li><li>saquinavir<p>saquinavir will increase the level or effect of hydrocodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Coadministration with CYP3A4 inhibitors may increase hydrocodone plasma concentrations and can result in potentially fatal respiratory depression</p></li><li>selegiline transdermal<p>selegiline transdermal increases toxicity of hydrocodone by unknown mechanism. Avoid or Use Alternate Drug. Risk of hypotension, hyperpyrexia, somnolence, or death.</p></li><li>sodium oxybate<p>hydrocodone, sodium oxybate.
Either increases effects of the other by pharmacodynamic synergism. Contraindicated. Additive CNS depression.</p></li><li>st john's wort<p>st john's wort will decrease the level or effect of hydrocodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Caution when discontinuing CYP3A4 inducers that are coadministered with hydrocodone; plasma concentrations of hydrocodone may increase and can result in potentially fatal respiratory depression</p></li><li>telithromycin<p>telithromycin will increase the level or effect of hydrocodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Coadministration with CYP3A4 inhibitors may increase hydrocodone plasma concentrations and can result in potentially fatal respiratory depression</p></li><li>temazepam<p>temazepam and hydrocodone both increase  sedation. Avoid or Use Alternate Drug. may result in profound sedation, respiratory depression, coma, and death; avoid use of opioid medications in patients taking benzodiazepines, other CNS depressants, or alcohol</p></li><li>tipranavir<p>tipranavir will increase the level or effect of hydrocodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Coadministration with CYP3A4 inhibitors may increase hydrocodone plasma concentrations and can result in potentially fatal respiratory depression</p></li><li>tramadol<p>tramadol, hydrocodone. Other (see comment). Avoid or Use Alternate Drug. 
Comment: Tramadol may reinitiate opiate dependence in pts. previously addicted to other opiates; it may also provoke withdrawal Sx. in pts. who are currently opiate dependent.</p></li><li>tranylcypromine<p>tranylcypromine increases toxicity of hydrocodone by unknown mechanism. Avoid or Use Alternate Drug. Risk of hypotension, hyperpyrexia, somnolence, or death; separate by 14 d.</p></li><li>triazolam<p>triazolam and hydrocodone both increase  sedation. Avoid or Use Alternate Drug. may result in profound sedation, respiratory depression, coma, and death; avoid use of opioid medications in patients taking benzodiazepines, other CNS depressants, or alcohol</p></li><li>valerian<p>valerian and hydrocodone both increase  sedation. Avoid or Use Alternate Drug.</p></li><li>voriconazole<p>voriconazole will increase the level or effect of hydrocodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Coadministration with CYP3A4 inhibitors may increase hydrocodone plasma concentrations and can result in potentially fatal respiratory depression</p></li>